Jin Han
Center Affiliate, Center for Pharmacoepidemiology and Pharmacoeconomic Research
Clinical Associate Professor, University of Illinois at Chicago
Contact
Address:
833 S. Wood Street Rm 164 (MC886), Chicago, IL
Office Phone:
Email:
Related Sites:
About
Research Interests:
Pain management, sickle cell disease (SCD), safety and effectiveness of agents used in SCD, evaluation of clinical pharmacy services and interventions, and pharmacogenomics.
Teaching and Supervision
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/25/2025 – 12/5/2025
Clinical Applications (PHAR 520), 8/26/2024 – 12/6/2024
Clinical Applications (PHAR 520), 8/26/2024 – 12/6/2024
Clinical Applications (PHAR 520), 8/26/2024 – 12/6/2024
Clinical Applications (PHAR 520), 8/26/2024 – 12/6/2024
Pharmacokinetics (PHAR 435), 8/21/2024 – 12/1/2024
Selected Grants
Targeting the Pathophysiology of Sickle Cell-Related Kidney Disease Using SGLT2 Inhibitors", National Institutes of Health (National Heart, Lung, and Blood Institute)., 9/15/2025 - 6/30/2030, Obligated Amount: $755853; Anticipated Amount: $3781729
CTA: An Open Label, Observational, Prospective Registry of Participants With Sickle Cell Disease (SCD) Treated With Oxbryta� (Voxelotor) 440-4R2, Global Blood Therapeutics., 4/28/2023 - 5/31/2028, Obligated Amount: $163080; Anticipated Amount: $163080
Sickle Treatment and Outcomes Research in the Midwest (STORM), Cincinnati Childrens Hospital Medical Center., 9/1/2021 - 8/31/2026, Obligated Amount: $348000; Anticipated Amount: $348000
Platelet Decline as a Predictor of Complications in Sickle Cell Disease Sickle cell disease, Takeda Pharmaceuticals., 3/3/2021 - 8/31/2022, Obligated Amount: $216729.81; Anticipated Amount: $216729.81
The Efficacy and Safety of Ferriprox® for the Treatment of Transfusional Iron Overload in Patients with Sickle Cell Disease or Other Anemias, ApoPharma., 12/12/2014 - 10/1/2015, No Obligated Amount Set; No Anticipated Amount Set
Selected Publications
Bartolucci, Pablo, Audureau, Étienne, Audard, Vincent, Galactéros, Frédéric, Lettre, Guillaume, Anthony, Charmaine, Egbujo, Olufolake, Han, Jin, Ruiz, Maria Armila, Lash, James P, Gordeuk, Victor R, Zhang, Xu, Saraf, Santosh L. (2026). Albuminuria Predicts a Rapid Decline in Kidney Function in 2 International, Longitudinal Cohorts of Adults With Sickle Cell Anemia. American Journal of Hematology, 101, (2), 304-310. doi:10.1002/ajh.70155.
Pappano, Emma, Eskandari, Najmeh, Ruiz, Maria Armila, Ren, Guohui, Zhang, Xu, Han, Jin, Ivy, Zalaya, Njoku, Franklin, Farooqui, Marwah, Molokie, Robert, Gordeuk, Victor, Gladwin, Mark, Malik, Punam, Quinn, Charles, Saraf, Santosh. (2025). Renin-angiotensin-aldosterone system inhibitors exacerbate anemia in sickle cell disease. Blood, 146, (Supplement 1), 297-297. doi:10.1182/blood-2025-297.
Mcclain, Jessica, Thaker, Parth, Farooqui, Marwah, Ivy, Zalaya, Han, Jin, Mikolajczyk, Adam, Molokie, Robert, Saraf, Santosh, Gordeuk, Victor, Njoku, Franklin. (2025). A novel prognostic model for predicting mortality in adults with sickle cell disease and severe sinusoidal obstruction syndrome. Blood, 146, (Supplement 1), 532-532. doi:10.1182/blood-2025-532.
Xu, Chang, Ruiz, Maria Armila, Han, Jin, Ivy, Zalaya, Njoku, Franklin, Farooqui, Marwah, Molokie, Robert, Gordeuk, Victor, Saraf, Santosh. (2025). Effects of vaso-occlusive episodes, acute kidney injury, and APOL1 status on urine albumin concentration in patients with sickle cell disease. Blood, 146, (Supplement 1), 1164. doi:10.1182/blood-2025-1164.
Han, Jin, Njoku, Franklin, Farooqui, Marwah, Ivy, Zalaya, Molokie, Robert, Gordeuk, Victor, Saraf, Santosh. (2025). Impact of voxelotor discontinuation on patients with sickle cell disease. Blood, 146, (Supplement 1), 6150. doi:10.1182/blood-2025-6150.
Sun, Ryan, Srivastava, Anand, Zapater, Joseph L, Njoku, Franklin, Han, Jin, Ivy, Zalaya, Farooqui, Marwah, Rizvi, Insia, Layden, Brian, Molokie, Robert E, Gordeuk, Victor R, Saraf, Santosh L. (2025). Diabetes mellitus and APOL1 genotype increase the risk for chronic kidney disease progression in sickle cell disease. Blood, 145, (24), 2927-2930. doi:10.1182/blood.2024027839.
Zhang, Xu, Shah, Binal N, Han, Jin, López, José A, Chung, Dominic W, Chen, Junmei, Saraf, Santosh L, Gordeuk, Victor R. (2025). Steady‐State Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity Predicts Low Platelet Count at Hospitalization for Sickle Cell Disease Vaso‐Occlusive Episodes. American Journal of Hematology, 100, (5), 913-916. doi:10.1002/ajh.27636.
Han, Jin, Zhang, Xu, Shah, Binal N, Saraf, Santosh L, Gordeuk, Victor R. (2024). Alkaline phosphatase as a marker for painful vaso‐occlusive events and other acute complications in sickle cell disease. British Journal of Haematology, 205, (2), 716-718. doi:10.1111/bjh.19554.
Sun, Ryan, Srivastava, Anand, Derebail, Vimal K, Han, Jin, Molokie, Robert E, Gordeuk, Victor, Saraf, Santosh L. (2024). GLP‐1 agonists and SGLT‐2 inhibitors in adults with sickle cell disease. American Journal of Hematology, 99, (8), 1610-1612. doi:10.1002/ajh.27348.
Professional Leadership
ACCP 2026 Annual Meeting Program Committee, 10/1/2024 - Present
Taiwan Society of Health-System Pharmacists Ambulatory Care Board Certification Committee, 7/1/2022 - Present
ACCP 2023 Annual Meeting Program Committee, 10/15/2021 - 10/15/2023
Notable Honors
2022, Fellowship in the American College of Clinical Pharmacy (FCCP), the American College of Clinical Pharmacy (ACCP)
Education
Degrees:
PharmD, University of Illinois at Chicago, United States
PhD, Baylor College of Medicine, Texas
BS, Peking University, China
Postgraduate Training:
PGY1 Pharmacy Resident, Rush University Medical Center, United States
Howard Hughes Medical Institute Postdoctoral Fellow, University of Chicago, United States
Licensures and Certifications
Registered Pharmacist, State of Illinois, Date Not Set - Present
Pharmacotherapy Specialist, Board of Pharmacy Specialties, Date Not Set - Present